Repare Therapeutics Reports the P-I (MYTHIC) Trial Data of Lunresertib Plus Camonsertib to Treat Gynecologic Cancers
Shots:
- The P-I (MYTHIC) study assessed lunresertib + camonsertib to treat advanced solid tumors, incl. endometrial & Pt-resistant ovarian cancer (N=51). P-III trial of combination in endometrial cancer is planned in H2’25, with a small trial with up to 40 endometrial cancer patients in Q1’25
- Results, in evaluable endometrial cancer patients (n=27; median age: 67yrs.), showed ORR of 25.9% (cORR in 5/7), with clinical benefit in 48.1% of them. At 24wks., 43% experienced durable clinical benefit (PFS24w)
- Furthermore, results in 24 evaluable Pt-resistant ovarian cancer patients (median age: 63yrs.) depicted ORR of 37.5% (cORR in 4/9), with clinical benefit in 79% of them. At 24wks., 45% had PFS24w
Ref: Repare Therapeutics | Image: Repare Therapeutics
Related News:- AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
